These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 38665947)

  • 1. Antibody-drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis.
    Zhang M; Zuo Y; Chen S; Li Y; Xing Y; Yang L; Wang H; Guo R
    Front Oncol; 2024; 14():1323366. PubMed ID: 38665947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
    Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
    Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
    Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
    Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-drug conjugates for urothelial carcinoma.
    Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
    Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antibody-drug conjugates as new therapeutic agents in uro-oncology].
    Grimm MO; Foller S; Leeder M; Leucht K
    Urologie; 2023 Jul; 62(7):679-684. PubMed ID: 37294330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
    McGregor BA; Sonpavde GP; Kwak L; Regan MM; Gao X; Hvidsten H; Mantia CM; Wei XX; Berchuck JE; Berg SA; Ravi PK; Michaelson MD; Choueiri TK; Bellmunt J
    Ann Oncol; 2024 Jan; 35(1):91-97. PubMed ID: 37871703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review.
    Grant MJ; Stockhammer P; Austin MR; Nemeth Z; Petrylak DP
    Bladder Cancer; 2024; 10(1):9-23. PubMed ID: 38993528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin.
    Shafique MA; Haseeb A; Siddiq MA; Mussarat A; Rangwala HS; Mustafa MS
    Cancer Manag Res; 2023; 15():699-706. PubMed ID: 37485038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next.
    D'Angelo A; Chapman R; Sirico M; Sobhani N; Catalano M; Mini E; Roviello G
    Cancer Chemother Pharmacol; 2022 Sep; 90(3):191-205. PubMed ID: 35953604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan.
    Fontes MS; Vargas Pivato de Almeida D; Cavalin C; Tagawa ST
    Onco Targets Ther; 2022; 15():1531-1542. PubMed ID: 36575731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
    Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
    Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy.
    Tassinari E; Mollica V; Nuvola G; Marchetti A; Rosellini M; Massari F
    Cancer Manag Res; 2022; 14():1945-1960. PubMed ID: 35720644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review.
    Bantounou MA; Plascevic J; MacDonald L; Wong MC; O'Connell N; Galley HF
    Curr Urol; 2023 Dec; 17(4):271-279. PubMed ID: 37994340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma.
    Mathew Thomas V; Tripathi N; Agarwal N; Swami U
    Expert Rev Anticancer Ther; 2022 Apr; 22(4):335-341. PubMed ID: 35249433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
    Rosenberg JE; O'Donnell PH; Balar AV; McGregor BA; Heath EI; Yu EY; Galsky MD; Hahn NM; Gartner EM; Pinelli JM; Liang SY; Melhem-Bertrandt A; Petrylak DP
    J Clin Oncol; 2019 Oct; 37(29):2592-2600. PubMed ID: 31356140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future Perspectives.
    Alameddine R; Mallea P; Shahab F; Zakharia Y
    Curr Treat Options Oncol; 2023 Sep; 24(9):1167-1182. PubMed ID: 37403009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review.
    Koshkin VS; Osbourne AS; Grivas P
    Transl Androl Urol; 2021 Oct; 10(10):4022-4035. PubMed ID: 34804845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
    Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
    Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?
    Moussa MJ; Campbell MT; Alhalabi O
    Biomedicines; 2024 Feb; 12(3):. PubMed ID: 38540132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape.
    Ghose A; Lapitan P; Apte V; Ghosh A; Kandala A; Basu S; Parkes J; Shinde SD; Boussios S; Sharma A; Das P; Vasdev N; Rebuzzi SE; Ürün Y; Kanesvaran R; Maniam A; Banna GL
    Curr Oncol Rep; 2024 Jun; 26(6):633-646. PubMed ID: 38652426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.